Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:30am, Wednesday, 06'th Jan 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformat
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to de
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
09:26pm, Tuesday, 08'th Dec 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformati
Atara Biotherapeutics Announces Proposed Offering of Common Stock
04:07pm, Monday, 07'th Dec 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformativ
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
11:00pm, Sunday, 06'th Dec 2020
WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development a
Regenerative Medicines: Universal Cell Therapy Gaining Momentum
08:03am, Tuesday, 01'st Dec 2020
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mo
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript
12:39am, Tuesday, 10'th Nov 2020
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript
Les bénéfices d'AG Barr au H1 glissent en raison des restrictions liées au COVID-19 | Invezz
09:26pm, Tuesday, 22'nd Sep 2020
AG Barr a enregistré une charge exceptionnelle de 11,5 millions £ au S1 et a dit que les paiements de dividendes pourraient être rétablis en 2021.
De H1 winst van AG Barr daalt vanwege COVID-19 beperkingen | Invezz
06:03pm, Tuesday, 22'nd Sep 2020
De winst van AG Barr over het eerste halfjaar daalt als gevolg van COVID-19. Het bedrijf zag in H1 £11,5 miljoen aan uitzonderlijke lasten.
Las ganancias de A.G. Barr se caen debido a las restricciones de COVID-19 en el primer semestre fiscal | Invezz
03:29pm, Tuesday, 22'nd Sep 2020
En un anuncio el martes, AG Barr plc (LON: BAG) dijo que su ganancia antes de impuestos en el primer semestre fiscal fue menor en una base anual. La compañía atribuyó la disminución a la pandemia
Il profitto di AG Barr diminuisce a causa del COVID-19 nel Q1 | Invezz
11:54am, Tuesday, 22'nd Sep 2020
La società ha registrato £11,5 milioni di spese eccezionali nel Q1. AG Barr afferma che i pagamenti dei dividendi potrebbero essere ripristinati nel 2021.
Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
04:30am, Tuesday, 15'th Sep 2020
Two sample breakout stocks for Week 38 with better than 10% short-term upside potential. Now up an average +199.7% YTD.
Wall Street Breakfast: The Week Ahead
04:42am, Sunday, 06'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
